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Figure 2. Lung ﬁbrosis in NSG mice 8 weeks after transplantation
The lung from NSG mouse bearing PBMCs (A) or CD34+ cells (B) 8 weeks after transplantation was stained with Masson’s trichrome. Fibrosis is shown in blue.
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airways in the lung despite showing no sign of acute illness
or weight loss. Masson’s trichrome revealed increased
ﬁbrosis in the lung (Figure 2), but not in other organs.
Conclusion: We have shown that in the NSG mouse, a
combination of Cy/TBI with a lownumber of G-CSFmobilized
human PBMCs causes chronic lung inﬂammation and ﬁbrosis
that can serve as an important pre-clinic model of lung
cGVHD.415
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Introduction: Transplants from cord blood stem cells is
known to have lower incidence of graft-versus-host disease
(GVHD). However, in patients who undergo cord blood
transplant (CBT) and develop GVHD, its features are not well
studied.
Objectives: Determine clinical features of GVHD and dura-
tion of therapy in patients who received CBT.
Patients and Methods: From 1993 to 2013, 196 patients
received CBT were retrospectively analised and divided into
two categories. Group 1: 64 patients who developed GVHD.
Group 2: 132 patients without this complication. Acute
GVHD was graded according to Glucksberg criteria and
Chronic Graft versus Host Disease was graded by NIH
consensus criteria. Statistical analysis: Kaplan Meier (sur-
vival) and Fisher test (comparison of categorical variables). P
level of signiﬁcance was <0.05.
Results: Thirty three percent of patients developed GVHD
(40 males and 24 females). Median age was 6 years old (1-
31). 61 patients received CBT from a mismatched donor.
Thirty (48%) were transplanted for malignancies. Five
transplants were from a related and 59 from an unrelateddonor. Conditioning: Reduced intensity (RIC) in 6 cases and
myeloablative in 58. Engraftment was complete in 48 cases
(75%). Median survival in group 1 was 1832d (27-7283)
versus 201d in group 2 (1-6242). Twenty nine patients have
died. Forty one patients developed acute GVHD (aGVHD), 6
patients classic chronic GVHD (cGVHD) and 17 had an over-
lap syndrome. Grade II-IV aGVHD was seen in 49 cases
(84.4%). Among cGVHD patients 9 (39.2%) were mild, 6 (26%)
moderate and 8 (34.8%) severe. Median time for the onset of
aGVHD was 23d (7-227) and cGVHD was 176d (64-659). The
main sites of aGVHD were skin: 55(86%), gut: 22 (34%) and
liver:14 (21%). Among cGVHD patients, 14 had skin (21%),
liver:12 (18%), mouth:9 (14%), gut and lung (BO): 6(9%) each.
Median time of cyclosporine therapy was 923d (7-3365).
Steroids were used for a median time of 290d (8-4303).
GVHD was less common in patients with a full match donor
(p¼0,001), those who used thymoglobuline (p<0,0001) and
methotrexate (MTX) (p¼0,0133). In contrast, GVHD rates
were higher in patients who had an early (p¼0,0111) and
complete (p<0,0001) engraftment and had bacterial
(p¼0,0133) or viral (p¼0,0086) infections during the pre-
engraftment time. Survival rates were higher in patients who
developed GVHD (p¼0,0256), had a myeloablative condi-
tioning regimen (p¼0,048), children <14 yo (p¼0,0002),
patients who used cyclosporine for at least one year
(p<0,0001) and full chimerism (p<0,0001).
Conclusions: We conclude GVHD can be frequent and even
serious in CBT recipients. Risk factors included early and
complete engraftment, mismatched donor, viral or bacterial
infection during the pre-engraftment period, use of RIC and
lack of MTX. Risk factors for survival were absence of GVHD,
RIC, older age, and lack of full engraftment.416
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Background: Acute graft-versus-host disease (GVHD) re-
mains a leading cause of morbidity and mortality in alloge-
neic hematopoietic stem cell transplant (HSCT) recipients.
